Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ('Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy ...

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...

Alpha Tau Medical Ltd., a company specializing in innovative alpha-radiation cancer therapy, announced that CFO Raphi Levy will present at two investor conferences in May 2025. He will participate in ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever The company has a quick ratio of 5.81, a current ratio of 5.81 and a ...

Alpha Tau Medical Ltd. (NASDAQ: DRTS) shares climbed 25.26% in after-hours trading to $5.30, after the company announced the first patient treatment in its pilot study for recurrent glioblastoma ...

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.

Alpha Tau Medical (NASDAQ:DRTS) recently reported its Q3 2025 results, providing updates on ongoing clinical studies, regulatory progress, and manufacturing readiness - developments that indicate ...

Now, the China Spallation Neutron Source — a major national scientific facility in Dongguan, Guangdong province — has ...